Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients

Background: Eltrombopag (EPAG) is an oral thrombopoietin receptor agonist, approved for refractory primary immune thrombocytopenia (ITP) in pediatric patients. In two pediatric RCTs, EPAG led to an improvement of platelet counts and a reduction in bleeding severity. However, a significant number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionisi, Marco, Cairoli, Sara, Simeoli, Raffaele, De Gennaro, Francesca, Paganelli, Valeria, Carta, Roberto, Rossi, Francesca, Dionisi-Vici, Carlo, Palumbo, Giuseppe, Goffredo, Bianca Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685423/
https://www.ncbi.nlm.nih.gov/pubmed/34938187
http://dx.doi.org/10.3389/fphar.2021.772873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685423/
https://www.ncbi.nlm.nih.gov/pubmed/34938187
http://dx.doi.org/10.3389/fphar.2021.772873

Ejemplares similares